


S-F24

Cat. No.:	HY-149844
CAS No.:	2946669-78-7
Molecular Formula:	C ₂₅ H ₂₇ BrF ₂ N ₆ O
Molecular Weight:	545.42
Target:	Fungal
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	S-F24 is an antifungal agent with excellent broad-spectrum. S-F24 inhibits CYP3A4 with an IC ₅₀ value of 0.4 μM. S-F24 displays a good safety profile with high selectivity, low hemolytic effects, and low tendency to induce resistance. S-F24 can be used for research on fungal infections ^[1] .								
In Vitro	<p>S-F24 (10-30 μM, 48 h) has weak cytotoxicity on mammalian cells^[1].</p> <p>S-F24 (0.002 μg/mL, 20 passages) increases the MIC₈₀ value against <i>C. albicans</i> SC5314 by 8-fold^[1].</p> <p>S-F24 (0.004 μg/mL, 16 h) inhibits ergosterol biosynthesis to 92.03% in <i>C. albicans</i> SC5314^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Cytotoxicity Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>HUVEC, MCF-10A, 16HBE, LO2</td> </tr> <tr> <td>Concentration:</td> <td>0.4 μM, 10-30 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>48 h</td> </tr> <tr> <td>Result:</td> <td>Displayed weak cytotoxicity with IC₅₀ values ranging from 13.97 to 29.22 μM. Inhibited CYP3A4 with an IC₅₀ value of 0.4 μM.</td> </tr> </table>	Cell Line:	HUVEC, MCF-10A, 16HBE, LO2	Concentration:	0.4 μM, 10-30 μM	Incubation Time:	48 h	Result:	Displayed weak cytotoxicity with IC ₅₀ values ranging from 13.97 to 29.22 μM. Inhibited CYP3A4 with an IC ₅₀ value of 0.4 μM.
Cell Line:	HUVEC, MCF-10A, 16HBE, LO2								
Concentration:	0.4 μM, 10-30 μM								
Incubation Time:	48 h								
Result:	Displayed weak cytotoxicity with IC ₅₀ values ranging from 13.97 to 29.22 μM. Inhibited CYP3A4 with an IC ₅₀ value of 0.4 μM.								
In Vivo	<p>S-F24 (1, 5 mg/kg, i.p., 5 days, daily) is widely used in treating invasive fungal infection in female IRC mice infected with <i>C. albicans</i> SC5314, <i>A. fumigatus</i> CGMCC3.7795, and multi-resistant <i>C. albicans</i> 24D^[1].</p> <p>S-F24 (0.5, 1 mg/kg, i.p., 5 days, daily) is highly efficacious in treating superficial fungal infection in female IRC mice infected with <i>C. albicans</i> SC5314^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>ICR mouse models infected systemically with <i>C. albicans</i> SC5314, or <i>A. fumigatus</i> CGMCC3.7795, or multi-resistant <i>C. albicans</i> 24D^[1]</td> </tr> <tr> <td>Dosage:</td> <td>1, 5 mg/kg/day, continue for 5 days</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection (i.p.)</td> </tr> <tr> <td>Result:</td> <td>Increased the median survival time (MST) to 6 days at 1.0 mg/kg/day in <i>C. albicans</i> SC5314</td> </tr> </table>	Animal Model:	ICR mouse models infected systemically with <i>C. albicans</i> SC5314, or <i>A. fumigatus</i> CGMCC3.7795, or multi-resistant <i>C. albicans</i> 24D ^[1]	Dosage:	1, 5 mg/kg/day, continue for 5 days	Administration:	Intraperitoneal injection (i.p.)	Result:	Increased the median survival time (MST) to 6 days at 1.0 mg/kg/day in <i>C. albicans</i> SC5314
Animal Model:	ICR mouse models infected systemically with <i>C. albicans</i> SC5314, or <i>A. fumigatus</i> CGMCC3.7795, or multi-resistant <i>C. albicans</i> 24D ^[1]								
Dosage:	1, 5 mg/kg/day, continue for 5 days								
Administration:	Intraperitoneal injection (i.p.)								
Result:	Increased the median survival time (MST) to 6 days at 1.0 mg/kg/day in <i>C. albicans</i> SC5314								

challenge.
Increased the MST in a dose-dependent manner significantly in fumigatus CGMCC3.7795 challenge.
Increased the MST to 12 days at 1.0 mg/kg/day in multi-resistant C. albicans 24D challenge.

Animal Model:	C. albicans[1].
Dosage:	0.5, 1 mg/kg/day, continue for 5 days
Administration:	Intraperitoneal injection (i.p.)
Result:	Reduced the fungal burden significantly and showed better therapeutic effects than the Luli (HY-14283) (1 mg/kg) group. Inhibited fungi almost completely in the group at 1.0 mg/kg.

REFERENCES

[1]. Zhu P, et al. Novel Triazoles with Potent and Broad-Spectrum Antifungal Activity In Vitro and In Vivo. J Med Chem. 2023 Jun 8;66(11):7497-7515.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA